Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22217
Full metadata record
DC FieldValueLanguage
dc.contributor.authorComi, Giancarlo-
dc.contributor.authorAlroughani, Raed-
dc.contributor.authorBoster, Aaron L-
dc.contributor.authorBass, Ann D-
dc.contributor.authorBerkovich, Regina-
dc.contributor.authorFernández, Óscar-
dc.contributor.authorKim, Ho Jin-
dc.contributor.authorLimmroth, Volker-
dc.contributor.authorLycke, Jan-
dc.contributor.authorMacdonell, Richard A L-
dc.contributor.authorSharrack, Basil-
dc.contributor.authorSinger, Barry A-
dc.contributor.authorVermersch, Patrick-
dc.contributor.authorWiendl, Heinz-
dc.contributor.authorZiemssen, Tjalf-
dc.contributor.authorJacobs, Alan-
dc.contributor.authorDaizadeh, Nadia-
dc.contributor.authorRodriguez, Claudio E-
dc.contributor.authorTraboulsee, Anthony-
dc.date2019-11-25-
dc.date.accessioned2019-12-04T05:00:32Z-
dc.date.available2019-12-04T05:00:32Z-
dc.date.issued2020-12-
dc.identifier.citationMultiple Sclerosis 2020; 26(14): 1866-1876en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22217-
dc.description.abstractAlemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); <12-month follow-up after last alemtuzumab course. In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.en_US
dc.language.isoeng-
dc.subjectAlemtuzumaben_US
dc.subjectefficacyen_US
dc.subjectmultiple sclerosisen_US
dc.subjectrelapseen_US
dc.subjectretreatmenten_US
dc.subjectsafetyen_US
dc.titleEfficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleMultiple sclerosis (Houndmills, Basingstoke, England)en_US
dc.identifier.affiliationDivision of Neurology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canadaen_US
dc.identifier.affiliationDepartment of Neurology, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australiaen_US
dc.identifier.affiliationMS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO, USAen_US
dc.identifier.affiliationUniv. Lille, INSERM U995, CHU Lille, FHU Imminent, F-59000 Lille, Franceen_US
dc.identifier.affiliationDepartment of Neurology, University of Münster, Münster, Germanyen_US
dc.identifier.affiliationCenter of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germanyen_US
dc.identifier.affiliationSanofi, Cambridge, MA, USAen_US
dc.identifier.affiliationDepartment of Neurology, University Vita-Salute San Raffaele, Milan, Italyen_US
dc.identifier.affiliationDepartment of Medicine, Amiri Hospital, Sharq, Kuwaiten_US
dc.identifier.affiliationOhioHealth Neurological Physicians, Columbus, OH, USAen_US
dc.identifier.affiliationNeurology Center of San Antonio, San Antonio, TX, USAen_US
dc.identifier.affiliationKeck School of Medicine, University of Southern California, Los Angeles, CA, USA/Regina Berkovich, MD, PhD, Inc., West Hollywood, CA, USAen_US
dc.identifier.affiliationInstituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spainen_US
dc.identifier.affiliationResearch Institute and Hospital, National Cancer Center, Goyang, South Koreaen_US
dc.identifier.affiliationKlinik für Neurologie und Palliativmedizin, Cologne, Germanyen_US
dc.identifier.affiliationInstitute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Swedenen_US
dc.identifier.affiliationNIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals, University of Sheffield, Sheffield, UKen_US
dc.identifier.doi10.1177/1352458519888610en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-5436-5804en_US
dc.identifier.orcid0000-0002-7891-8466en_US
dc.identifier.orcid0000-0001-8799-8202en_US
dc.identifier.pubmedid31762387-
dc.type.austinJournal Article-
local.name.researcherMacdonell, Richard A L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.